ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has a beta value of 2.55 and has seen 2,413,831 shares traded in the last trading session. The company, currently valued at $730.72 Million, closed the last trade at $3.41 per share which meant it lost -$0.3 on the day or -8.09% during that session. The ZIOP stock price is -112.61% off its 52-week high price of $7.25 and 47.21% above the 52-week low of $1.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.48 Million shares traded. The 3-month trading volume is 1.9 Million shares.
The consensus among analysts is that ZIOPHARM Oncology, Inc. (ZIOP) is a Buy stock at the moment, with a recommendation rating of 2.4. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 7 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.09.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) trade information
Despite being -8.09% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the ZIOP stock price touched $3.80-1 or saw a rise of 10.21%. Year-to-date, ZIOPHARM Oncology, Inc. shares have moved -27.75%, while the 5-day performance has seen it change 4.28%. Over the past 30 days, the shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) have changed 4.6%. Short interest in the company has seen 25.03 Million shares shorted with days to cover at 13.17.
Wall Street analysts have a consensus price target for the stock at $5.93, which means that the shares’ value could jump 73.9% from current levels. The projected low price target is $3 while the price target rests at a high of $7.5. In that case, then, we find that the current price level is +119.94% off the targeted high while a plunge would see the stock lose -12.02% from current levels.
ZIOPHARM Oncology, Inc. (ZIOP) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -17.4% over the past 5 years. Earnings growth for 2020 is a modest -173.4% while over the next 5 years, the company’s earnings are expected to increase by 0%.